Nuwellis, Inc.
No SEC Form 4 filings for $NUWE in the last 30 days.
Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 6 ef20079229_ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 31, 2026 between Nuwellis, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the sign
Nuwellis (NASDAQ: NUWE) entered a definitive securities purchase agreement for a registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds of about $3.1 million from warrant exercises tied to its June 2026 offering. In a concurrent private placement, investors receive warrants for up to 1,310,890 shares at $2.59, exercisable immediately, expiring in five years. Closing expected around Aug. 3, 2026.
Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
Over the past 7 days, alphai's AI scored 1 news story mentioning NUWE (Nuwellis, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NUWE coverage spans corporate actions, technology and market movers.
The filing indicates NUWE is issuing and selling securities under a securities purchase agreement, which can dilute shareholders and change near-term capital structure risk.
The deal is a dilutive capital raise with immediate warrant exercisability, likely pressuring near-term sentiment and increasing supply overhang.
Peer-reviewed journal acceptance strengthens clinical credibility for Aquadex, potentially improving investor confidence in pediatric critical-care adoption.
The article links NUWE’s spike to clinical evidence acceptance and ongoing pediatric adoption of Aquadex SmartFlow, plus attention on Aug. 13 results.
Accepted publication of a retrospective single-center study supports the clinical narrative around Aquadex anticoagulation, driving a sharp momentum move.
alphai scores every news story that mentions NUWE with an AI model for sentiment and relevance, and aggregates insider trades from Nuwellis, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 6 ef20079229_ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 31, 2026 between Nuwellis, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the sign
2 min readNuwellis (NASDAQ: NUWE) entered a definitive securities purchase agreement for a registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds of about $3.1 million from warrant exercises tied to its June 2026 offering. In a concurrent private placement, investors receive warrants for up to 1,310,890 shares at $2.59, exercisable immediately, expiring in five years. Closing expected around Aug. 3, 2026.
2 min readToday's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
6 min read- Nuwellis stock is showing exceptional strength. What’s fueling NUWE momentum? What Is Driving Nuwellis’ Stock Surge? Nuwellis said a new single-center retrospective study supporting an alternative anticoagulation strategy for Aquadex ultrafiltration therapy was accepted by Frontiers in Pediatrics, highlighting epoprostenol as a potential option for keeping circuits open without adding bleeding risk or requiring intensive metabolic monitoring.
3 min readNuwellis (NUWE) shares rose about 133% after Frontiers in Pediatrics accepted a single-center retrospective study evaluating epoprostenol as an alternative anticoagulant for Nuwellis’ Aquadex ultrafiltration therapy in critically ill children. NUWE traded around $4.40, after opening near $5.14 and reaching about $6.40.
2 min readNuwellis (NUWE) said Frontiers in Pediatrics accepted a single-center retrospective study on using epoprostenol as an alternative anticoagulant during its Aquadex ultrafiltration therapy in critically ill children. The study reviewed 46 children and 52 treatment courses at UPMC, reporting maintained circuit performance and no bleeding events attributed to the drug. NUWE shares closed at $1.89 and rose in pre-market.
4 min readNuwellis (NASDAQ:NUWE) shares jumped about 90% to $3.59 after the bell Wednesday after trading down 2.07% to $1.89 in the regular session. The move followed a Tuesday update that it installed its first Aquadex SmartFlow systems at a pediatric hospital in Wisconsin. Nuwellis also reported preliminary Q2 revenue growth of 14% YoY and 6-month growth of 20%, with full results due Aug. 13.
3 min readNuwellis, Inc. (NUWE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001506492 NASDAQ 0001506492 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2
2 min readNuwellis, Inc. (NUWE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001506492 NASDAQ 0001506492 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1
3 min readNuwellis (NASDAQ: NUWE) director Emerson J. Martin was granted 6,744 nonstatutory stock options as part of his equity compensation. These options allow him to purchase Nuwellis common stock at an exercise price of $1.16 per share, vesting in 12 equal monthly installments over one year and expiring on April 27, 2036. Following this transaction, Martin directly holds 6,744 derivative securities related to Nuwellis common stock.
2 min read
